Mesirow Financial Investment Management Inc. Sells 146 Shares of Hologic, Inc. (NASDAQ:HOLX)

Mesirow Financial Investment Management Inc. reduced its holdings in Hologic, Inc. (NASDAQ:HOLX) by 1.0% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 14,109 shares of the medical equipment provider’s stock after selling 146 shares during the period. Mesirow Financial Investment Management Inc.’s holdings in Hologic were worth $1,149,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. Price T Rowe Associates Inc. MD grew its position in Hologic by 77.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock worth $490,931,000 after acquiring an additional 2,753,016 shares in the last quarter. Swedbank AB bought a new stake in shares of Hologic in the 1st quarter valued at approximately $120,827,000. Black Creek Investment Management Inc. boosted its holdings in shares of Hologic by 60.9% in the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock worth $173,669,000 after purchasing an additional 885,524 shares during the period. Mackenzie Financial Corp increased its position in shares of Hologic by 1,023.3% during the 2nd quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider’s stock valued at $66,506,000 after purchasing an additional 815,960 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in Hologic during the 2nd quarter valued at $39,427,000. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

HOLX has been the topic of a number of analyst reports. Mizuho cut their price objective on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Evercore ISI increased their price objective on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. StockNews.com downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research note on Wednesday, November 6th. JPMorgan Chase & Co. upped their target price on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Finally, Raymond James raised their price target on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $89.25.

Hologic Price Performance

Shares of HOLX stock opened at $78.76 on Monday. Hologic, Inc. has a twelve month low of $66.93 and a twelve month high of $84.67. The company has a current ratio of 3.69, a quick ratio of 3.32 and a debt-to-equity ratio of 0.49. The stock has a fifty day simple moving average of $80.97 and a two-hundred day simple moving average of $78.16. The stock has a market capitalization of $18.29 billion, a price-to-earnings ratio of 23.65, a P/E/G ratio of 2.48 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.01. The company had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.89 earnings per share. On average, analysts predict that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.